WHO ICTRP trial
A study to about blinatumomab for patients with minimal residual disease (MRD)…
EUCTR2015-000733-76-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2015-000733-76-DE |
|---|---|
| Public title | A study to about blinatumomab for patients with minimal residual disease (MRD) of acute lymphoblastic leukemia |
| Scientific title | A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lympho-blastic leukemia (Blast Successor Trial) |
| Primary sponsor | Goethe-Universität Frankfurt, Universitätsklinikum, Med. Klinik II |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Germany |
| Conditions | Patients with minimal residual disease (MRD) positive B-precursor ALL with and without prior SCT documented after an interval of at least 8 days from last systemic chemo-therapy • at a level of =10-4 - <10-3 (molecular failure or molecular… |
| Interventions | Trade Name: Blincyto Product Name: Blinatumomab Pharmaceutical Form: Powder and solvent for concentrate for solution for infusion |
| Registration date | Feb 3, 2016 |
| Target size | 80 |
| Secondary IDs | GMALL-MOLACT1-BLINA |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: